25597-36-8Relevant articles and documents
Synthesis of the first conjugates of 5-ethynyl-2′-deoxyuridine with closo-dodecaborate and cobalt-bis-dicarbollide boron clusters
Semioshkin, Andrey,Ilinova, Anna,Lobanova, Irina,Bregadze, Vladimir,Paradowska, Edyta,Studzińska, Miros?awa,Jab?on?ska, Agnieszka,Lesnikowski, Zbigniew J.
, p. 8034 - 8041 (2013)
A new 2′-deoxyuridine modification, 3′,5′-bis-(dimethyl- tert-butylsilyl)-5-(3-(2-(dimethylamino)ethoxy)-3-methylbutyn-1-yl) -2′-deoxyuridine was effectively synthesized in four easy steps. Its reactivity toward a range of cyclic oxonium adducts of closo-dodecaborate and cobalt-bis-dicarbollide boron clusters was studied. The cleavage reactions of cluster oxonium rings by the N,N-dimethylamino group of the modified nucleoside led to 5-ethynyl-2′-deoxyuridine conjugates with [B12H 12]2- and [Co(C2B9H 11)2]-, respectively. Cytotoxicity of these new conjugates in several cell lines was examined. Closo-dodecaborate conjugates showed low cytotoxicity in all examined cell lines, an advantageous and preferred property for potential boron delivering drugs for the boron neutron capture therapy (BNCT) of tumors.
NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
-
Page/Page column 91, (2008/06/13)
The invention relates to compounds of formula (I) wherein Ar, X, R1, R2, R3 and R4 are as defined herein and, pharmaceutical compositions thereof useful, either alone or in combination with other therapeutic agents as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV for the treatment or prophylaxis of HIV infection
